Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
暂无分享,去创建一个
[1] A. Stepan,et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.
[2] A. Halabi,et al. Macitentan: entry-into-humans study with a new endothelin receptor antagonist , 2011, European Journal of Clinical Pharmacology.
[3] Dennis A. Smith,et al. Multiple factors govern the association between pharmacology and toxicity in a class of drugs: toward a unification of class effect terminology. , 2011, Chemical research in toxicology.
[4] C. Kaymaz,et al. [Endothelin receptor antagonists in pulmonary arterial hypertension]. , 2010, Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology.
[5] D. Richards,et al. Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan , 2009, Journal of clinical pharmacology.
[6] B. Wiens,et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.
[7] M. Hoeper,et al. Endothelin receptor antagonists in pulmonary arterial hypertension , 2008, European Respiratory Journal.
[8] M. Humbert,et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension , 2007, European Respiratory Journal.
[9] B. Stieger,et al. Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil , 2007, Drug Metabolism and Disposition.
[10] W. Heizer,et al. In Vitro–In Vivo Correlation of Hepatobiliary Drug Clearance in Humans , 2007, Clinical pharmacology and therapeutics.
[11] E. Kerem,et al. Pregnancy and chronic progressive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[12] Takashi Usui,et al. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance–associated protein 2 , 2007, Biopharmaceutics & drug disposition.
[13] H. Ghofrani,et al. NO CLINICALLY RELEVANT PHARMACOKINETIC INTERACTION BETWEEN AMBRISENTAN AND SILDENAFIL , 2006 .
[14] H. Ghofrani,et al. AMBRISENTAN HAS NO CLINICALLY RELEVANT EFFECT ON THE PHARMACOKINETICS OR PHARMACODYNAMICS OF WARFARIN , 2006 .
[15] D. Badesch,et al. ARIES-1: A PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AMBRISENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION , 2006 .
[16] D. Webb,et al. Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel “-Sentan” Class of Drug , 2006, Experimental biology and medicine.
[17] R. Barst,et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.
[18] Kim L R Brouwer,et al. Methods to evaluate biliary excretion of drugs in humans: an updated review. , 2006, Molecular pharmaceutics.
[19] V. Seifert,et al. Ambrisentan, a non-peptide endothelin receptor antagonist. , 2006, Cardiovascular drug reviews.
[20] D. Badesch,et al. Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.
[21] R. Barst,et al. Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.
[22] K. Brouwer,et al. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[23] D. Mccrory,et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[24] D. Mccrory,et al. Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines , 2004 .
[25] M. Clozel,et al. Inhibition of Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake Is the Major Determinant in the Pharmacokinetic Interaction between Bosentan and Cyclosporin A in the Rat , 2004, Journal of Pharmacology and Experimental Therapeutics.
[26] R. Dixon,et al. Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.
[27] D. Back,et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. , 2003, British journal of clinical pharmacology.
[28] R. Poupon,et al. Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. , 2002, Journal of hepatology.
[29] A. Halabi,et al. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. , 2002, British journal of clinical pharmacology.
[30] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[31] Jürg Reichen,et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions , 2001, Clinical pharmacology and therapeutics.
[32] N. Gretz,et al. The endothelin antagonist bosentan does not improve survival in severe experimental pancreatitis in rats , 1999, International journal of pancreatology : official journal of the International Association of Pancreatology.
[33] Bruno Stieger,et al. Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. , 1999, American journal of physiology. Gastrointestinal and liver physiology.
[34] W. Neidhart,et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. , 1994, The Journal of pharmacology and experimental therapeutics.
[35] Bernhard J. Dotzler. In vitro – in vivo , 2011 .
[36] D. Badesch,et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. , 2007, Chest.
[37] L. Rubin. Pulmonary arterial hypertension. , 2006, Proceedings of the American Thoracic Society.
[38] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[39] I. Binet,et al. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. , 2000, Kidney international.
[40] W. Liu,et al. in vitro及びin vivoで示されるステロイド受容体ヘテロ二量化 , 1995 .